Elizabeth H. Z. Thompson net worth and biography

Elizabeth Thompson Biography and Net Worth

Dr. Elizabeth H.Z. Thompson joined Horizon in June 2018 as an accomplished drug development professional with two decades of experience and roles in the development of multiple marketed medications. In her time at Horizon, she has been responsible for the guidance of clinical development activities across the portfolio, including the expedited filing and approval of TEPEZZA and its successful FDA Advisory Committee meeting. Dr. Thompson currently leads day-to-day operations for the Horizon pipeline.

Before joining Horizon, Dr. Thompson was a group scientific director in pharmaceutical development at AbbVie, where she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson has had a career spanning clinical development, business development and medical communications, and has also worked at Raptor, InterMune and Amgen.

Dr. Thompson holds a bachelor’s degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from the Scripps Research Institute.

How old is Elizabeth H. Z. Thompson?: Dr. Thompson is currently 48 years old. There are 5 older executives and no younger executives at Horizon Therapeutics Public. The oldest executive at Horizon Therapeutics Public is Mr. Timothy P. Walbert, Chairman, Pres & CEO, who is 56 years old. Learn More on Elizabeth H. Z. Thompson's age.
How do I contact Elizabeth H. Z. Thompson?: The corporate mailing address for Dr. Thompson and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Elizabeth H. Z. Thompson's contact information.
Has Elizabeth H. Z. Thompson been buying or selling shares of Horizon Therapeutics Public?: Elizabeth H. Z. Thompson has not been actively trading shares of Horizon Therapeutics Public within the last three months. Learn More on Elizabeth H. Z. Thompson's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Elizabeth H. Z. Thompson Insider Trading History at Horizon Therapeutics Public

Elizabeth H. Z. Thompson Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03

Move Your Money Before May 22

From Stansberry Research | Ad

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.